Blood scores may identify low-risk patients after hepatitis c cure, reducing need for lifelong cancer scans

NCT ID NCT07687758

Knowledge-focused Sponsor: Siriraj Hospital Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at whether simple, non-invasive blood test scores can predict the risk of developing liver cancer in people with advanced liver disease who have been cured of hepatitis C. Researchers analyzed data from 571 adults treated at a single hospital over ten years. The goal is to find a group of patients with such low risk that they might safely skip routine liver cancer surveillance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this could allow doctors to safely reduce liver cancer surveillance for some patients after hepatitis C is cured, saving time and resources.
What could go wrong: This is a retrospective study, not a controlled trial, so results may not apply to all patients. The scores may not be accurate enough to change clinical practice without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

571 people

The number who actually took part.

Started

Jan 2013

Finished

Jul 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with chronic hepatitis C virus infection and compensated advanced chronic liver disease who initiated sofosbuvir-based direct-acting antiviral therapy at Siriraj Hospital between 2013 and 2023 and achieved sustained virological response at 12 weeks after treatment completion.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Chronic hepatitis C virus infection treated with direct-acting antiviral therapy * Documented sustained virological response at 12 weeks after treatment completion * Evidence of compensated advanced chronic liver disease before direct-acting antiviral therapy, defined by at least one of the following: histologic F3 or F4 fibrosis, vibration-controlled transient elastography \>10 kPa, radiologic features compatible with advanced fibrosis or cirrhosis, or clinical or endoscopic evidence of portal hypertension * Minimum follow-up of 12 months after sustained virological response Exclusion Criteria: * Incomplete or missing medical records precluding outcome assessment * Known or suspected hepatocellular carcinoma before initiating direct-acting antiviral therapy * Failure to achieve sustained virological response at 12 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis C virus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection hepatitis C virus infection hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Compensated advanced chronic liver disease Hepatitis C virus infection Hepatocellular carcinoma (HCC)

Blood scores may identify low-risk patients after hepatitis c cure, reducing need for lifelong cancer scans

What the study statuses mean